Λίστα αντικειμένων
Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A.
Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with
myelodysplastic syndrome (MDS). Although less intense
therapies are being used more often in AML, the dichotomy between AML and MDS remains, with the presence
of >20% myeloblasts in marrow or peripheral blood generally regarded as defining AML. Consequently, patients
with 19% blasts are typically ineligible for AML studies,
and patients with 21% blasts are ineligible for MDS studies. Here biologic and clinical data are cited to question this practice.
Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A.
Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with
myelodysplastic syndrome (MDS). Although less intense
therapies are being used more often in AML, the dichotomy between AML and MDS remains, with the presence
of >20% myeloblasts in marrow or peripheral blood generally regarded as defining AML. Consequently, patients
with 19% blasts are typically ineligible for AML studies,
and patients with 21% blasts are ineligible for MDS studies. Here biologic and clinical data are cited to question this practice.
Σχετικά Αρχεία
Τηλέφωνα Επικοινωνίας:
Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) Fax : 2613 604066,email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gremail (για θέματα κλινικών μελετών) : gcppatras@gmail.comΜονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261Γραφείο Ιατρών: 2613 604064, 2613 604065, Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)
